Keep your eyes on this space:

the Safety and Tolerability of Proxalutamide (GT0918) in Subjects With Metastatic Castrate Resistant Prostate Cancer

https://clinicaltrials.gov/ct2/show/NCT03899467

Amber Tong reported on this:

A Chi­nese can­cer-fo­cused biotech look­ing to one-up J&J and Pfiz­er in cas­tra­tion-re­sis­tant prostate can­cer has launched its IPO in Hong Kong, look­ing to raise more than $232 mil­lion (HK$1.86 bil­lion) on the HKEX. Three cor­ner­stone in­vestors have laid claims to $98 mil­lion worth of Kin­tor Phar­ma’s shares, while oth­ers are free to bid on the rest for be­tween HK$17.8 and HK$20.15 apiece. The Jiang­su-based com­pa­ny’s lead drug, prox­a­lu­tamide, is an an­dro­gen re­cep­tor an­tag­o­nist now in Phase III tri­als in Chi­na and Phase II in the US. The stock is sched­uled to de­but on May 22.

 https://endpts.com/chinese-biotech-aims-232m-in-ipo-cash-to-push-next-gen-prostate-cancer-drug-immunomedics-raises-nearly-half-a-billion-off-approval/